Topical Tranexamic Acid After Intravitreal Injections

Subconjunctival Hemorrhage Clinical Trial

Official title:

Topical Use of Tranexamic Acid for Prevention of Subconjunctival Hemorrhage After Intravitreal Injections

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04400916
• Other study ID #: 0424-19-RMB
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 2020
• Est. completion date: December 2021

Study information

• Verified date: May 2020
• Source: Rambam Health Care Campus
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We aim to investigate whether topical administration of Tranexamic acid can reduce the occurence of subconjunctival hemorrahge after routine intravitreal injections for retinal conditions.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: December 2021
• Est. primary completion date: September 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

Subjects receiving intravitreal injections as part of their routine ophthalmological care

Exclusion Criteria:

Pregnancy, Oral contraceptives/HRT use, Known systemic autoimmune disease, Renal failure, active/suspected infection or inflammation in the treated eye, subconjunctival hemorrahge prior to inclusion, History of subarachnoid hemorrahge, thromboembolic events, increased risk for thromboembolic events, known sensitivity to the study drug

Related Conditions & MeSH terms

• Hemorrhage
• Subconjunctival Hemorrhage

Intervention

Drug:
• Tranexamic acid
A single drop administered topically

Other:
• Balanced Salt Solution
A single drop administered topically

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Rambam Health Care Campus

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subconjunctival hemorrahge		3 days